Discontinuation of etanercept after successful treatment in patients with juvenile idiopathic arthritis

Journal of Rheumatology

Volumn 37, Issue 9, 2010, Pages 1970-1971

  Remesal, Agustin ^a   De Inocencio, Jaime ^a   Merino, Rosa ^a   Garcia Consuegra, Julia ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; STEROID;

ADOLESCENT; ADULT; CHILD; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LETTER; MALE; PRIORITY JOURNAL; RELAPSE; REMISSION; TREATMENT DURATION;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77956494252     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.100219     Document Type: Letter

References (10)

1. Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, et al; Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54:1987-94.
2. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, et al; Pediatric Rheumatology Collaborative Study Group. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009;60:2794-804.
3. Wallace CA, Ruperto N, Giannini E; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4.
4. Prince FH, Twilt M, Simon SC, van Rossum MA, Armbrust W, Hoppenreijs EP, et al. When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2009;68:1228-9.
5. Miyamura T, Sonomoto K, Nakamura M, Horai Y, Takahama S, Ando H, et al. Discontinuation of etanercept in patients with rheumatoid arthritis who were in clinical remission. Clin Rheumatol 2010;29:87-90.
6. Brocq O, Millasseau E, Albert C, Grisot C, Flory P, Roux CH, et al. Effect of discontinuing TNF alpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009;76:350-5.
7. Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005;7:R439-44.
8. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, et al. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol 2007;34:510-5.
9. Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
10. Brandt J, Listing J, Haibel H, Sörensen H, Schwebig A, Rudwaleit M, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 2005;44:342-8.